OnkoCloneTM Minimal Residual Disease (MRD) Monitoring
In recent years, treatment of Chronic Lymphoid Leukemia (CLL) has dramatically evolved from chemotherapy to targeted agents (e.g. ibrutinib). Additionally, achieving a complete response with undetected minimal residual disease (uMRD), which is currently defined as the presence of less than 1 CLL cell in 10,000 leukocytes (<10-4) has become increasingly important in CLL. IGVH Hypermutation testing by next-generation sequencing (NGS), if performed at diagnosis, enables not only the determination of somatic hypermutation (SHM) status but also follow-up minimal residual disease (MRD) monitoring for patient’s therapy response and/or disease relapse/persistence.
Clinical Utility of MRD in Chronic Lymphoid Leukemia
- MRD allows further refinement and individualization of treatment strategies in CLL.
- Interim MRD analysis could be used to identify patients who benefit from treatment de-escalation or cessation to avoid unnecessary treatment-related toxicity.
- Assessment of MRD, together with genetic aspects, could identify patient groups in need of longer or more intensive treatment.
Test Information
Download a sample report here.